PI
BMRN icon

Putnam Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Putnam Investments’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-134,954
Closed -$11.7M – 1146
2023
Q2 		$11.7M Sell
134,954
-76
-0.1% -$7.15K 0.02% 279
2023
Q1 		$13.1M Buy
+135,030
New +$14M 0.02% 268
2020
Q3 		– Sell
-1,697
Closed -$210K – 837
2020
Q2 		$210K Buy
+1,697
New +$169K ﹤0.01% 856
2019
Q2 		– Sell
-909,552
Closed -$80.8M – 892
2019
Q1 		$80.8M Sell
909,552
-252,267
-22% -$23.4M 0.19% 131
2018
Q4 		$98.9M Buy
1,161,819
+389,551
+50% +$37.1M 0.26% 115
2018
Q3 		$74.9M Buy
772,268
+258,110
+50% +$25.8M 0.16% 143
2018
Q2 		$48.4M Buy
+514,158
New +$45M 0.11% 171
2017
Q2 		– Sell
-366,054
Closed -$32.1M – 1127
2017
Q1 		$32.1M Sell
366,054
-352,829
-49% -$31.4M 0.08% 212
2016
Q4 		$59.6M Buy
718,883
+93,762
+15% +$8.06M 0.14% 156
2016
Q3 		$57.8M Buy
625,121
+179,447
+40% +$16.9M 0.14% 164
2016
Q2 		$34.7M Sell
445,674
-599
-0.1% -$50.9K 0.08% 212
2016
Q1 		$36.8M Buy
446,273
+42,210
+10% +$3.43M 0.09% 206
2015
Q4 		$42.3M Sell
404,063
-312
-0.1% -$32.6K 0.1% 199
2015
Q3 		$42.6M Buy
404,375
+1,483
+0.4% +$198K 0.1% 204
2015
Q2 		$55.1M Buy
402,892
+600
+0.1% +$74.4K 0.11% 193
2015
Q1 		$50.1M Sell
402,292
-64,905
-14% -$6.88M 0.1% 210
2014
Q4 		$42.2M Sell
467,197
-136,064
-23% -$11.3M 0.09% 228
2014
Q3 		$43.5M Buy
603,261
+60,554
+11% +$3.98M 0.09% 201
2014
Q2 		$33.8M Buy
542,707
+184,146
+51% +$11.1M 0.07% 251
2014
Q1 		$24.5M Sell
358,561
-98,836
-22% -$7.28M 0.06% 293
2013
Q4 		$32.1M Sell
457,397
-75,625
-14% -$5.14M 0.08% 258
2013
Q3 		$38.5M Sell
533,022
-90,024
-14% -$5.98M 0.1% 211
2013
Q2 		$34.8M Buy
+623,046
New +$38.8M 0.1% 217

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Putnam Investments's BMRN Position: Q3 2023 in Review

Putnam Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 134,954 shares — an estimated $11.7M sold.

Putnam Investments first reported a position in BMRN in Q2 2013 and held it in 23 quarters. The position peaked at $98.9M in Q4 2018. 520 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • Putnam Investments reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Putnam Investments sold 134,954 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $11.7M.
  • Putnam Investments first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 23 quarters.
  • Putnam Investments's BioMarin Pharmaceuticals position peaked at $98.9M in Q4 2018.
  • 520 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Putnam Investments's 13F filing for Q3 2023, filed 14 Nov 2023.